Source: Health Canada shortage reports · Updated Jul 10, 2026
Some Saxagliptin products are in shortage in Canada (1 of 4 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer.
A DPP-4 inhibitor used to lower blood sugar in type 2 diabetes.
Products affected
1 / 4
In shortage since
Jun 2, 2026
Reports on file
16
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
APO-SAXAGLIPTIN
2.5MG · TABLET · APOTEX INC
DIN 02507471 · since Jun 2, 2026, est. end Jul 10, 2026 · Disruption of the manufacture of the drug.
Resolved
APO-SAXAGLIPTIN
2.5MG · TABLET · APOTEX INC
DIN 02507471 · ended Jul 9, 2026 · Disruption of the manufacture of the drug.
Resolved
SANDOZ SAXAGLIPTIN
5MG · TABLET · SANDOZ CANADA INCORPORATED
DIN 02468611 · ended Jul 6, 2026 · Delay in shipping of the drug.
Resolved
SANDOZ SAXAGLIPTIN
2.5MG · TABLET · SANDOZ CANADA INCORPORATED
DIN 02468603 · ended May 25, 2026 · Disruption of the manufacture of the drug.
Resolved
SANDOZ SAXAGLIPTIN
5MG · TABLET · SANDOZ CANADA INCORPORATED
DIN 02468611 · ended Apr 27, 2026 · Disruption of the manufacture of the drug.
Resolved
APO-SAXAGLIPTIN
5MG · TABLET · APOTEX INC
DIN 02507498 · ended Jan 29, 2026 · Disruption of the manufacture of the drug.
Resolved
APO-SAXAGLIPTIN
2.5MG · TABLET · APOTEX INC
DIN 02507471 · ended Mar 27, 2026 · Disruption of the manufacture of the drug.
Resolved
APO-SAXAGLIPTIN
5MG · TABLET · APOTEX INC
DIN 02507498 · ended Mar 27, 2026 · Disruption of the manufacture of the drug.
Resolved
APO-SAXAGLIPTIN
5MG · TABLET · APOTEX INC
DIN 02507498 · ended Jan 2, 2025 · Disruption of the manufacture of the drug.
Resolved
APO-SAXAGLIPTIN
2.5MG · TABLET · APOTEX INC
DIN 02507471 · ended Jul 18, 2022 · Disruption of the manufacture of the drug.
Resolved
APO-SAXAGLIPTIN
5MG · TABLET · APOTEX INC
DIN 02507498 · ended Jul 6, 2022 · Shortage of an active ingredient.
Resolved
SANDOZ SAXAGLIPTIN
5MG · TABLET · SANDOZ CANADA INCORPORATED
DIN 02468611 · ended Jun 22, 2022 · Disruption of the manufacture of the drug.
Showing 12 of 16 reports. All reports are on file with Health Canada.
What's happening
Saxagliptin is currently affected by an active shortage report filed with Health Canada by APOTEX INC.
The reported cause is: disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Saxagliptin is classified under “BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS” (ATC A10BH).
Recent changes
Jul 10, 2026
Shortage resolved
Common questions
What is Saxagliptin used for?
A DPP-4 inhibitor used to lower blood sugar in type 2 diabetes.
When will Saxagliptin be back in stock in Canada?
Manufacturers have not provided a reliable end date. This page updates automatically as soon as an estimate is filed.
Why is Saxagliptin in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.